Correction to: Nature Reviews Immunology 10.1038/s41577-023-00877-7, published online 15 May 2023.
In the version of the article initially published, there was an error in Fig. 2 where pembrolizumab was included but has been removed as it is not a protein kinase inhibitor. In Table 3, a dividing line between Povorcitinib and Tofacitinib was missing and has now been added. These corrections have been made to the HTML and PDF versions of the article.